only about 3,000 canadians are afflicted by als, but it is terminal — roughly 80 per cent will die within two to five years of diagnosis, although some live decades longer. the exact cause is unknown, there is no cure, and treatments are few.
current drugs
approved by health canada, and available for reimbursement under most provincial government health plans, include rilutek (riluzole), which can increase survival by six to 19 months, as well as radicava (edaravone) and albrioza, both of which have been shown to slow the disease’s progression in some people in the early stages.
the most common form of the disease is called sporadic als, which affects anyone regardless of age, gender or ethnicity, although it is most common in those between 40 and 60. an inherited type, called familial als, is rare, making up about five to 10 per cent of cases. even rarer is a form called
brachial amyotrophic diplegia
, which dodds’ neurologist believes he could have (he’s awaiting results of further testing), causing atrophy in the upper extremities.
coming to terms with als diagnosis
“either i’m lucky or i’m oblivious and it still hasn’t hit me yet,” says dodds of his diagnosis. “i’m still in fine spirits, which is good for me and my wife, tracey, and kids, will and morgan. morgan’s 22 and will’s just about 19. for them, me being good with it mentally also helps them quite a lot. if i was down and dour, i think our house would be a different place.”
dodds says he knew little about the disease before he was diagnosed. “a few years ago we all dumped a bucket of ice on our heads for it,” he says, referring to the
ice bucket challenge of 2014
, which raised awareness and $17 million in canada. “i knew it was a terrible disease that was terminal. now every day is a learning experience. it’s like having two full-time jobs now, where i’ve got the shop and i’ve got this disease that slows me down and i have to try to learn about at the same time.”